Last updated: 2026-09-06 08:32:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Citius Oncology, Inc. (CTOR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.84, with a market capitalization of $82.25M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.49 to $2.25. This page covers its latest market performance, valuation, price trends and company information.
$82.25M | |
$0.77 | |
$6.19 | |
$0.49 | |
$0.79 | |
54.31K | |
-- | |
-- | |
$2.25 | |
$0.49 | |
-- | |
-- |
Citius Oncology, Inc. (CTOR) last closed at $0.79 as of 2026-09-04 23:31:00, unchanged from the previous close of $0.79.
During the latest regular trading session, CTOR traded between $0.49 and $6.19, with a volume of 54.31K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Citius Oncology, Inc. (CTOR) moved from $0.82 to $0.84, representing a gain of 2.44% ($0.02).
The stock traded between $0.76 and $0.87 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 23.78 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 19.8%
CTOR is currently trading at $0.84, placing it 19.8% of the way from its 52-week low of $0.49 to its 52-week high of $2.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Citius Oncology, Inc. (CTOR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.